caplacizumab

This page shows the latest caplacizumab news and features for those working in and with pharma, biotech and healthcare.

Sanofi exits R&D pact with Alnylam on rare disease

Alprolix – and the takeover of Belgian biotech Ablynx last year to claim rights to acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi (caplacizumab).

Latest news

Sanofi extends growth spurt thanks to Genzyme, Dupixent

from Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura (aTTP), which made its debut in Germany in October.
Sanofi gets US okay for $270,000 blood disorder drug Cablivi

The US approval – which comes a few months after Cablivi (caplacizumab) was cleared in the EU – if for the use of Cablivi in combination with plasma exchange and immunosuppressive therapy in
As France protests, Sanofi takes axe to 670 jobs

dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.
Dupixent helps put Sanofi back on growth track

Brandicourt is also hoping for new sales momentum from two new product approvals – checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura
Sanofi gets EU OK for Ablynx flagship drug Cablivi

The EU regulator has cleared Cablivi (caplacizumab) for adults with aTTP, and Sanofi says that the drug is the first in Europe to be approved specifically for the rare blood-clotting

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

bid for Ablynx in December, which the Ablynx Board rejected. Novo Nordisk's particular interest was in lead asset caplacizumab, a Nanobody therapeutic which inhibits von Willebrand factor (vWF) for the ... Acquisition company. 7, 000. Ablynx/Sanofi.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Novo Nordisk target Ablynx reshuffles its board

lead, wholly-owned product, caplacizumab, in addition to advancing our extensive pipeline.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Account Director, Medical Education: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Senior Medical Writer: Competitive salary and benefits

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Senior Medical Writer: Salary TBC

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Director – Healthcare PR: Salary TBC

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

PR Associate Director – Consumer Health & Beauty: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...